Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
Acurx Pharmaceuticals, Inc. (ACXP)
Company Research
Source: PR Newswire
STATEN ISLAND, N.Y., March 30, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that the Korean Intellectual Property Office (KIPO) has granted a new patent which covers DNA Polymerase IIIC inhibitors including compositions-of-matter, methods of use, and pharmaceutical compositions, which further strengthen Acurx's intellectual property portfolio and represents the most recent addition to its expanding series of granted patents in the U.S. and abroad. To date, Acurx has secured four U.S. patents, along with granted patents in Israel, Japan, India, Australia and Korea, all of which protect key aspects of the Company's ACX-375C program targeting DNA Polymerase IIIC. Additional country-level patent applications remain under review.Robert J. DeLuccia, Executive Chairman of Acurx, stated: "Achievi
Show less
Read more
Impact Snapshot
Event Time:
ACXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACXP alerts
High impacting Acurx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ACXP
News
- Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors [Yahoo! Finance]Yahoo! Finance
- Acurx Pharmaceuticals Inc (ACXP) Q4 2025 Earnings Call Highlights: Financial Growth and ... [Yahoo! Finance]Yahoo! Finance
- Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business UpdatePR Newswire
ACXP
Earnings
- 3/13/26 - Beat
ACXP
Sec Filings
- 3/12/26 - Form S-8
- 3/12/26 - Form 10-K
- 3/9/26 - Form 8-K
- ACXP's page on the SEC website